BMO On Affimed Following Clinical Hold For AFM11: 'We believe AFM11 clinical hold is likely temporary, as the three SAEs (including one death) in the ALL/NHL trials were identified as neurotoxicities'; Maintains Outperform Rating, Has $5 Price Target